相关实验视频

Updated: Jun 8, 2025

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

针对乳腺癌中的erbB途径:对大脑转移的双激酶抑制和预防p185HER2 / 新瘤发展

Peeyush N Goel^1,2, Makoto Katsumata³, Wei Qian⁴

¹Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104-6082, USA.

Breast cancer (Dove Medical Press)

|November 4, 2024

概括

新型小分子抑制剂ER121在HER2阳性模型中有效降低了乳腺瘤生长和大脑转移. 这种无毒的药物对治疗晚期乳腺癌和预防复发有前途.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

乳腺癌带来了重大的治疗挑战,特别是在晚期.
ER121是一种小化合物,之前已经证明对突变EGFR和HER2表达癌症有效.

研究的目的:

评估ER121在转移性和三阴性乳腺癌 (TNBC,HER2+) 的疗效和毒性.
评估ER121在Herceptin耐药JIMT-1细胞系和MMTV-erbB2转基因小鼠模型中用于新辅助疗法.

主要方法:

在TNBC大脑转移中ER121的疗效使用体内成像系统 (IVIS) 量化.
在实验室和体内使用JIMT-1细胞系进行了ER121的测试.
在接受口服ER121.1.治疗的MMTV-erbB2转基因小鼠中,评估了新辅助剂的疗效和生存率.

主要成果:

在TNBC,HER2+模型中,ER121显著抑制了乳腺瘤生长和大脑转移.
ER121在抗赫塞丁的JIMT-1细胞系异种移植模型中显示出显著的抑制作用.
在新辅助剂环境下口服ER121的使用显著改善了MMTV-erbB2转基因小鼠的无瘤存活率.

结论:

ER121是一种无毒的小分子erbB激酶抑制剂,具有作为治疗渐进的erbB驱动瘤的口服全身疗法的潜力.
作为对 erbB2 相关瘤的预防性新辅助疗法,ER121 是有前途的.
在临床前模型中,系统性ER121的使用可以显著限制erbB2脑转移.

关键词:

在ER121中,我们可以使用ER121.美国TNBC电视台大脑转移是大脑转移.乳腺癌乳腺癌乳腺癌这是一种激酶抑制剂 (kinase inhibitor).新辅助模型的新辅助模型

更多相关视频

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...